Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study aims to find out how effective and well-tolerated the subcutaneous form of trastuzumab-pertuzumab (known as Phesgo) is when given before surgery (neoadjuvant treatment) to Algerian women with early stage, HER2-positive breast cancer. The study will take place in three oncology centers in Algeria (Blida, Aïn Defla, Médéa) and include around 70 adult women diagnosed with non-metastatic HER2-positive breast cancer. Participants will receive Phesgo along with standard chemotherapy over about 18 weeks, followed by surgery. The main goal is to measure how many women achieve complete destruction of invasive cancer in the breast and nearby lymph nodes (pathological complete response, pCR). We will also look at other outcomes such as how many women can keep their breast, any side effects, quality of life, satisfaction with treatment, and factors that might predict response. Results from this real-world study will help assess whether Phesgo can simplify treatment delivery, reduce hospital burden, and improve care access in Algeria where healthcare resources are often stretched.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety w wieku 19 lat lub starsze.
- •Potwierdzony rak piersi HER2-dodatni, który nie rozprzestrzenił się na inne części ciała.
- •Nadaje się do leczenia przed operacją według lokalnych zasad.
- •Ogólny stan zdrowia pozwalający na aktywność (wg skali ECOG do 2).
- •Prawidłowa praca serca (frakcja wyrzutowa lewej komory ≥ 50%).
- •Podpisanie świadomej zgody na udział w badaniu.
✗ Disqualifies
- •Rak piersi, który rozprzestrzenił się na inne części ciała.
- •Wcześniejsze leczenie lekami celowanymi w HER2.
- •Przeciwwskazania do stosowania trastuzumabu lub pertuzumabu.
- •Ciąża lub karmienie piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- September 10, 2025
- Sex
- Female only
Locations (1)
Medical oncology department - Anti Cancer Center of Blida
Blida, Algeria
Trial contact
Adda Bounedjar, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.